chr1-207757020-G-A
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM2PP3_StrongPP5
The ENST00000367042.6(CD46):c.104G>A(p.Cys35Tyr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000682 in 1,613,506 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
ENST00000367042.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CD46 | NM_172351.3 | c.104G>A | p.Cys35Tyr | missense_variant | 2/13 | ENST00000367042.6 | NP_758861.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CD46 | ENST00000367042.6 | c.104G>A | p.Cys35Tyr | missense_variant | 2/13 | 1 | NM_172351.3 | ENSP00000356009 | A2 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152190Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251344Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135874
GnomAD4 exome AF: 0.00000616 AC: 9AN: 1461316Hom.: 0 Cov.: 32 AF XY: 0.00000550 AC XY: 4AN XY: 726998
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152190Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74350
ClinVar
Submissions by phenotype
Atypical hemolytic-uremic syndrome with MCP/CD46 anomaly Pathogenic:1Other:1
risk factor, no assertion criteria provided | literature only | OMIM | Aug 15, 2006 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | 3billion | Feb 23, 2023 | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.001%). Functional studies provide moderate evidence of the variant having a damaging effect on the gene or gene product (PMID: 16621965). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.88; 3Cnet: 0.81). Same nucleotide change resulting in same amino acid change has been previously reported to be associated with CD46 related disorder (PMID: 16621965). Therefore, this variant is classified as Likely pathogenic according to the recommendation of ACMG/AMP guideline. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 04, 2024 | Variant summary: CD46 c.104G>A (p.Cys35Tyr) results in a non-conservative amino acid change located in the Sushi/SCR/CCP domain (IPR000436) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 251344 control chromosomes (gnomAD). c.104G>A has been reported in the literature in individuals affected with Atypical Hemolytic Uremic Syndrome who were compound heterozygous with a pathogenic CD46 variant and/or carried variants in CFH that ClinVar submitters have classified as pathogenic/likely pathogenic (e.g. Caprioli_2006, Bresin_2013, Stevenson_2014). It was also found in a homozygous case (Khandelwal_2018). These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein expression, finding that the variant results in a loss of expression of the mature form of the protein (Caprioli_2006). The following publications have been ascertained in the context of this evaluation (PMID: 16621965, 23431077, 24460647, 35372954, 29644059, 28752844, 29046944). ClinVar contains an entry for this variant (Variation ID: 17049). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 17, 2022 | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CD46 protein function. ClinVar contains an entry for this variant (Variation ID: 17049). This variant is also known as p.C1Y. This missense change has been observed in individual(s) with atypical hemolytic uremic syndrome (PMID: 2431077, 16621965, 24460647). This variant is present in population databases (rs121909591, gnomAD 0.007%). This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 35 of the CD46 protein (p.Cys35Tyr). Studies have shown that this missense change alters CD46 gene expression (PMID: 16621965). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at